Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Lemaitre Vascular (LMAT) EBT (2016 - 2025)

Lemaitre Vascular (LMAT) has disclosed EBT for 16 consecutive years, with $20.1 million as the latest value for Q4 2025.

  • Quarterly EBT rose 101.96% to $20.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $75.0 million through Dec 2025, up 42.02% year-over-year, with the annual reading at $75.0 million for FY2025, 42.02% up from the prior year.
  • EBT for Q4 2025 was $20.1 million at Lemaitre Vascular, down from $22.6 million in the prior quarter.
  • The five-year high for EBT was $22.6 million in Q3 2025, with the low at -$26.2 million in Q4 2021.
  • Average EBT over 5 years is $9.6 million, with a median of $9.9 million recorded in 2023.
  • The sharpest move saw EBT tumbled 393.9% in 2021, then surged 125.08% in 2022.
  • Over 5 years, EBT stood at -$26.2 million in 2021, then soared by 125.08% to $6.6 million in 2022, then soared by 39.68% to $9.2 million in 2023, then grew by 8.49% to $10.0 million in 2024, then surged by 101.96% to $20.1 million in 2025.
  • According to Business Quant data, EBT over the past three periods came in at $20.1 million, $22.6 million, and $18.1 million for Q4 2025, Q3 2025, and Q2 2025 respectively.